Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.
about
C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancerFrequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers.Transgenic mouse models of human breast cancer.The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerMYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells.Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.Growth factors. Clinical implications in breast cancer.Chromatin structure and function: the heretical path to an RNA transcription factor.Tertiary structure prediction and identification of druggable pocket in the cancer biomarker - Osteopontin-c.Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway.Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
P2860
Q24795406-CD36D46C-F5EB-433A-9BE5-CAEBA6A6D700Q33260375-24F16C22-B2E2-4B28-8AE9-592A1A86F453Q34130558-1DA771B4-F7C9-4CC7-84BA-2C0628150837Q34273280-B58E949C-E3EF-43F8-A7D7-83B65E00BDCDQ35748541-74A22DA8-1BF7-4F6D-9BBA-EC254B5F9D5CQ36907273-4944A1FA-37EA-41E6-B516-393524DA2189Q37174700-6784BC35-5F57-4565-A989-19866C42200BQ38965179-FBBD7998-6179-4AAD-83E7-B95BBD950E20Q39555908-9EA18E9B-BCDE-496B-9F8F-99FC612829E9Q40800342-9288BA31-0B98-4BD1-91C5-B699DFC52CECQ41338905-996B1972-46C4-4E5A-B084-DC19D01A26B6Q41951757-343F9F6B-EACA-48B4-B7EF-18B98788EE9DQ44398181-CEE17D16-85B8-4A50-89EB-6D90A3676926Q46695515-E46A5F0D-1B7D-41E3-98E7-D2D4E56600AD
P2860
Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Prognostic factors in human pr ...... yc and HER2/neu amplification.
@ast
Prognostic factors in human pr ...... yc and HER2/neu amplification.
@en
type
label
Prognostic factors in human pr ...... yc and HER2/neu amplification.
@ast
Prognostic factors in human pr ...... yc and HER2/neu amplification.
@en
prefLabel
Prognostic factors in human pr ...... yc and HER2/neu amplification.
@ast
Prognostic factors in human pr ...... yc and HER2/neu amplification.
@en
P2093
P1476
Prognostic factors in human pr ...... yc and HER2/neu amplification.
@en
P2093
Foekens JA
Portengen H
de Koning WC
van Putten WL
van Staveren IL
P356
10.1016/0960-0760(92)90182-I
P577
1992-09-01T00:00:00Z